| Title: | Genomic approaches to relating cardiovascular structure and function to heart failure for the purposes of drug discovery. |
| Lead Institution: | Tenaya Therapeutics Inc. |
| Principal investigator: | Dr James Priest |
Application 84103
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Tenaya Therapeutics is a biopharmaceutical company working on discovery of new treatments for heart disease. We will look at genetic causes of heart failure, the genetic causes of how the heart functions, and integrate this with clinical data to find new relationships between genes and heart disease. We will use this information to create new ways of treating heart disease.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 15421 | Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations | Luke Zhang (+7) | 2025 | BMC Cardiovascular Disorders |
Enabling scientific discoveries that improve human health